Ethic Inc. Cuts Stock Holdings in Sanofi $SNY

Ethic Inc. lowered its stake in Sanofi (NASDAQ:SNY) by 14.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 92,493 shares of the company’s stock after selling 15,931 shares during the period. Ethic Inc.’s holdings in Sanofi were worth $4,366,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC increased its stake in Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares during the period. Ieq Capital LLC grew its holdings in shares of Sanofi by 25.7% in the first quarter. Ieq Capital LLC now owns 11,963 shares of the company’s stock worth $663,000 after purchasing an additional 2,443 shares during the last quarter. Vident Advisory LLC increased its stake in shares of Sanofi by 14.7% in the first quarter. Vident Advisory LLC now owns 15,560 shares of the company’s stock worth $863,000 after buying an additional 1,994 shares during the period. Baird Financial Group Inc. raised its holdings in Sanofi by 14.8% during the 1st quarter. Baird Financial Group Inc. now owns 164,161 shares of the company’s stock valued at $9,104,000 after buying an additional 21,121 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in Sanofi by 1.7% during the 1st quarter. Royal Bank of Canada now owns 2,432,701 shares of the company’s stock valued at $134,916,000 after buying an additional 40,213 shares during the period. Institutional investors own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on SNY shares. Cowen restated a “hold” rating on shares of Sanofi in a research report on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $62.67.

Sanofi Stock Performance

Sanofi stock opened at $48.74 on Wednesday. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The stock’s 50 day simple moving average is $49.60 and its two-hundred day simple moving average is $48.87. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06. The stock has a market cap of $119.65 billion, a price-to-earnings ratio of 11.41, a PEG ratio of 1.31 and a beta of 0.44.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the business posted $2.25 EPS. The firm’s revenue for the quarter was down 7.5% compared to the same quarter last year. As a group, analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.